How it works, simply
It interacts with cardiolipin, a lipid in the inner membrane of mitochondria, the cell's energy-producing structures.
What the evidence tells us
FDA accelerated approval is indication-specific and based on a surrogate endpoint. Confirmatory evidence is required to verify clinical benefit.
Forzinity has a narrow accelerated US approval for Barth syndrome in patients weighing at least 30 kg. This does not validate general anti-aging or recovery claims.
Approved use: United States: Forzinity to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg, under accelerated approval. Other mitochondrial research and RUO SS-31 vials do not inherit this approval.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
This brief guide does not summarize every contraindication or interaction. Use the current label for the exact product; the label directory is linked below.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Binds mitochondrial cardiolipin and localizes to the inner mitochondrial membrane.
Sponsor or developer: Stealth BioTherapeutics
Studied or labeled topics: Barth syndrome, Mitochondrial disease research
2025-09-19: Accelerated US approval for the labeled Barth syndrome population.
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
- FDA: Forzinity trial snapshot ↗ · Regulator · 2025-09-19
Readability updated October 10, 2026. Evidence review: October 10, 2026 (FDA indication and approval context). A wording update is not a new clinical review.